MilliporeSigma and the Broad Institute of MIT and Harvard entered an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development.
 
“Together with the Broad Institute, we are simplifying the path to licensing CRISPR technology, which will make it more widely available to the global research and discovery community,” said Udit Batra, CEO, MilliporeSigma. “Through this agreement, we will make it easier for our customers to be successful in their research that shortens drug development timelines for previously untreatable diseases.”
 
“We believe that key CRISPR patent holders should come together to simplify and open up access, and this agreement is another example of a partnership that helps maximize and streamline access to these important scientific tools,” said Issi Rozen, chief business officer of the Broad Institute. “Broad Institute already licenses CRISPR non-exclusively for all applications, with the exception of human therapeutics. We are actively working to ensure the widest and simplest possible access to key CRISPR intellectual property.” 
 
MilliporeSigma’s IP for CRISPR technology will become available royalty-free to non-profit academic institutions, non-profit business communities and governmental agencies for their internal research, consistent with the Broad Institute’s long-standing practice and requirements.